Olafur G Jonsson
Overview
Explore the profile of Olafur G Jonsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schafer Hackenhaar F, Refhagen N, Hagleitner M, van Leeuwen F, Marquart H, Madsen H, et al.
Blood
. 2025 Jan;
PMID: 39841000
Current intensive treatment of pediatric T-cell acute lymphoblastic leukemia (T-ALL) has substantial side-effects, highlighting a need for novel biomarkers to improve risk stratification. Canonical biomarkers such as genetics and immunophenotype...
2.
Zeller B, Arad-Cohen N, Cheuk D, De Moerloose B, Navarro J, Hasle H, et al.
Haematologica
. 2024 May;
109(9):2873-2883.
PMID: 38721737
Hyperleukocytosis in pediatric acute myeloid leukemia (AML) is associated with severe complications and an inferior outcome. We report results on patients with hyperleukocytosis included in the NOPHO-DBH AML 2012 study....
3.
Dam M, Stensig Lynggaard L, Jonsson O, Trakymiene S, Palk K, Jarvis K, et al.
Pediatr Blood Cancer
. 2024 Mar;
71(6):e30937.
PMID: 38480517
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post-thrombotic syndrome (PTS), a group...
4.
Krali O, Marincevic-Zuniga Y, Arvidsson G, Enblad A, Lundmark A, Sayyab S, et al.
NPJ Precis Oncol
. 2023 Dec;
7(1):131.
PMID: 38066241
Genomic analyses have redefined the molecular subgrouping of pediatric acute lymphoblastic leukemia (ALL). Molecular subgroups guide risk-stratification and targeted therapies, but outcomes of recently identified subtypes are often unclear, owing...
5.
Egnell C, Narhinen H, Merker A, Jonsson O, Lepik K, Niinimaki R, et al.
Eur J Haematol
. 2022 Aug;
109(6):656-663.
PMID: 36006839
Objectives: Children with acute lymphoblastic leukemia (ALL) have a tendency to gain weight during treatment. As overweight and obesity associate with health problems, prophylactic interventions are warranted. Therefore, it is...
6.
Toksvang L, Als-Nielsen B, Bacon C, Bertasiute R, Duarte X, Escherich G, et al.
BMC Cancer
. 2022 May;
22(1):483.
PMID: 35501736
Background: A critical challenge in current acute lymphoblastic leukemia (ALL) therapy is treatment intensification in order to reduce the relapse rate in the subset of patients at the highest risk...
7.
Toksvang L, Grell K, Nersting J, Degn M, Nielsen S, Abrahamsson J, et al.
Leukemia
. 2021 Jun;
36(1):33-41.
PMID: 34175901
Methotrexate/6-mercaptopurine maintenance therapy improves acute lymphoblastic leukemia (ALL) outcome. Cytotoxicity is mediated by DNA incorporation of thioguanine nucleotides (DNA-TG). We investigated the association of DNA-TG to relapse risk in 1 ...
8.
Hojfeldt S, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jonsson O, et al.
Blood
. 2020 Nov;
137(17):2373-2382.
PMID: 33150360
Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal...
9.
Egnell C, Ranta S, Banerjee J, Merker A, Niinimaki R, Lund B, et al.
Eur J Haematol
. 2020 Sep;
105(6):797-807.
PMID: 32909636
Objectives: High body mass index (BMI) is associated with poorer survival in childhood acute lymphoblastic leukemia (ALL), but the actual impact on the risk of relapse still needs to be...
10.
Mateos M, Tulstrup M, Quinn M, Tuckuviene R, Marshall G, Gupta R, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32438682
Methods: We undertook a genome-wide association study (GWAS) meta-analysis for VTE in consecutively treated children in the Nordic/Baltic acute lymphoblastic leukemia 2008 (ALL2008) cohort and the Australian Evaluation of Risk...